REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
2. Kaczmarek M, Poznańska J, Fechner F, et al. Cancer vaccine therapeutics: limitations and effectiveness-a literature review. Cells. 2023;12:2159.
3. Pulendran B, S Arunachalam P, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20:454-75.
4. Batista-Duharte A, Portuondo D, Pérez O, Carlos IZ. Systemic immunotoxicity reactions induced by adjuvanted vaccines. Int Immunopharmacol. 2014;20:170-80.
5. Shaw CA, Tomljenovic L. Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity. Immunol Res. 2013;56:304-16.
6. Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol. 2015;13:605-19.
8. Gao X, Feng Q, Wang J, Zhao X. Bacterial outer membrane vesicle-based cancer nanovaccines. Cancer Biol Med. 2022;19:1290-300.
9. Shah B, Sullivan CJ, Lonergan NE, Stanley S, Soult MC, Britt LD. Circulating bacterial membrane vesicles cause sepsis in rats. Shock. 2012;37:621-8.
10. Ryu S, Ni K, Wang C, et al. Bacterial outer membrane vesicles promote lung inflammatory responses and macrophage activation via multi-signaling pathways. Biomedicines. 2023;11:568.
11. Park KS, Svennerholm K, Crescitelli R, Lässer C, Gribonika I, Lötvall J. Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy. J Extracell Vesicles. 2021;10:e12120.
12. Velimirov B, Velimirov BA. Immune responses elicited by outer membrane vesicles of gram-negative bacteria: important players in vaccine development. Life. 2024;14:1584.
13. Ordikhani F, Uehara M, Kasinath V, et al. Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity. JCI Insight. 2018;3:122700.
14. Caproni E, Corbellari R, Tomasi M, et al. Anti-tumor efficacy of in situ vaccination using bacterial outer membrane vesicles. Cancers. 2023;15:3328.
16. Chen MY, Cheng TW, Pan YC, et al. Endotoxin-free outer membrane vesicles for safe and modular anticancer immunotherapy. ACS Synth Biol. 2025;14:148-60.
17. Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18:313-22.
18. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 1977;61:1307-17.
19. Chen IX, Newcomer K, Pauken KE, et al. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Proc Natl Acad Sci U S A. 2020;117:23684-94.
20. Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8:9.
21. Ye Z, Li G, Lei J. Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics. Exp Mol Med. 2024;56:2365-81.
